2018
DOI: 10.1016/j.cegh.2017.08.002
|View full text |Cite
|
Sign up to set email alerts
|

Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data

Abstract: Objectives: Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of bladder cancer (BC); however, the evidence underlining the association between pioglitazone use and BC risk remains inconclusive. We conducted a systematic review and meta-analysis of observational studies to investigate the effect of pioglitazone on risk of BC in T2DM patients. Methods: We searched all publications regarding risk of BC with pioglitazone use through PubMed, Web of Science and Cochrane library databases from in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
8
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(9 citation statements)
references
References 40 publications
(143 reference statements)
0
8
0
1
Order By: Relevance
“…Ten previous systematic reviews or meta-analyses on the association of pioglitazone use with bladder cancer have already been published [1][2][3][4][5][6][7][8][9][10]. Nevertheless, a final word on risk associated with pioglitazone use cannot be given because these studies are flawed by factors that range from improper use of analytical procedures to scarce consideration of time-related and selection biases.…”
Section: Introductionmentioning
confidence: 99%
“…Ten previous systematic reviews or meta-analyses on the association of pioglitazone use with bladder cancer have already been published [1][2][3][4][5][6][7][8][9][10]. Nevertheless, a final word on risk associated with pioglitazone use cannot be given because these studies are flawed by factors that range from improper use of analytical procedures to scarce consideration of time-related and selection biases.…”
Section: Introductionmentioning
confidence: 99%
“…Pioglitazone has remained the only available glitazone in Europe, however, it was withdrawn from the market in France and Germany in 2011 due to a suspected risk of bladder cancer. This concern still persists, as the conclusions of recent meta-analyses are contradictory [283,284,285]. A third commercially available glitazone analogue, lobeglitazone, was approved for use in Korea in 2013.…”
Section: Pleiotropic Drugs and Mel In Cancer Prevention/treatmentmentioning
confidence: 99%
“…Results from this study reported a positive association between bladder cancer and duration of pioglitazone use in the prevalent cohort (P = 0.008), with ≥ 24 months of pioglitazone exposure increasing the incidence of bladder cancer 16% (95% CI 0-35%) compared to non-user [12]. Interestingly, a recent meta-analysis of 15 observational studies conducted by Adil et al [13] which included 2,470,397 diabetic patient and …”
Section: Reviewmentioning
confidence: 99%